Anavex Life Sciences Reports Promising Results for Alzheimer’s Drug Blarcamesine
Anavex Life Sciences has announced promising outcomes from a Phase 2b/3 clinical trial for its
investigational Alzheimer’s drug, blarcamesine. Conducted across multiple
centers, the study aimed to assess the efficacy and safety of this novel
therapy in patients with early symptomatic Alzheimer’s disease.
The trial enrolled 508 participants and was designed to evaluate both cognitive and functional
improvements. According to Anavex Life Sciences, blarcamesine demonstrated a significant reduction in
amyloid-ß biomarkers, a hallmark of Alzheimer’s pathology. Treated patients
also showed slowed rates of brain atrophy on MRI scans, indicating potential
neuroprotective effects.
Dr. Marwan Noel Sabbagh, chairman of Anavex’s Scientific Advisory Board, emphasized the
significance of these findings. “The advantage of blarcamesine is its dual
action; it not only slows cognitive decline but also targets
neurodegeneration,” he said. This dual functionality, combined with its
oral administration, enhances its appeal as a treatment option.
The study utilized standardized measures such as the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-Cog) to quantify cognitive changes. Results showed a
marked improvement in the blarcamesine group compared to placebo, with a
statistically significant difference in scores.
Anavex Life Sciences reported that most adverse events, including dizziness, were mild to
moderate in severity and transient in nature. This favorable safety profile
further bolsters the drug’s potential.
Christopher U Missling, CEO of Anavex, expressed optimism about the future development of blarcamesine.
“These results encourage us to continue advancing blarcamesine as a
promising treatment for Alzheimer’s disease,” he stated.
The latest results are a critical milestone for Anavex Life Sciences in their ongoing efforts to
combat Alzheimer’s. With continued research and development, the company aims
to bring this innovative therapy closer to those in need.
Refer to this article for related information.
Follow them on Twitter.com